<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04169802</url>
  </required_header>
  <id_info>
    <org_study_id>SCT-201</org_study_id>
    <nct_id>NCT04169802</nct_id>
  </id_info>
  <brief_title>Study Evaluating Retinal Health Monitoring System Visual Acuity Module.</brief_title>
  <official_title>An Observational, Non-Significant Risk Study Of The Retinal Health Monitoring System (RHMS) - Visual Acuity Module - In Normal Patients And Patients With Neovascular Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kubota Vision Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kubota Vision Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the performance and usability of the RHMS Visual Acuity Module.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 510(k)-enabling study is designed to assess the performance and usability of the RHMS&#xD;
      Visual Acuity Module in normal patients and patients with neovascular AMD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Actual">April 15, 2020</completion_date>
  <primary_completion_date type="Actual">April 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the repeatability of CNVA measured by the RHMS Visual Acuity Module and the Reference Chart</measure>
    <time_frame>1 day</time_frame>
    <description>To determine the precision (repeatability and reproducibility) of corrected near visual acuity (CNVA) measured by the RHMS Visual Acuity Module and an in-clinic, near logarithmic Sloan Letter chart (Reference Chart).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the reproducibility of CNVA measured by the RHMS Visual Acuity Module and the Reference Chart</measure>
    <time_frame>1 day</time_frame>
    <description>To evaluate the agreement of CNVA measured by the RHMS Visual Acuity Module and the Reference Chart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Agreement of CNVA measured by the RHMS Visual Acuity Module and the Reference Chart</measure>
    <time_frame>1 day</time_frame>
    <description>To evaluate the usability of the RHMS Visual Acuity Module</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Normal subjects</arm_group_label>
    <description>Age ≥ 50 years, Corrected distance or near visual acuity (VA) of ≥ 20/25 Snellen equivalent, in the study eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with neovascular AMD</arm_group_label>
    <description>Age ≥ 50 years, History of neovascular age-related macular degeneration, in the study eye, Corrected distance or near VA of ≥ 20/200 Snellen equivalent, in the study eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Retinal Health Monitoring System Visual Acuity Module</intervention_name>
    <description>Assessment of corrected near visual acuity</description>
    <arm_group_label>Normal subjects</arm_group_label>
    <arm_group_label>Subjects with neovascular AMD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sloan letter, logarithmic near visual acuity chart (Reference Chart)</intervention_name>
    <description>Assessment of corrected near visual acuity</description>
    <arm_group_label>Normal subjects</arm_group_label>
    <arm_group_label>Subjects with neovascular AMD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects aged ≥ 50 years, with a normal central macula or with neovascular AMD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cohort 1 - Normal subjects&#xD;
&#xD;
          1. Age ≥ 50 years&#xD;
&#xD;
          2. Corrected distance or near visual acuity (VA) of ≥ 20/25 Snellen equivalent, in the&#xD;
             study eye&#xD;
&#xD;
          3. Able to perform self-testing with the Visual Acuity Module of the RHMS after training&#xD;
&#xD;
          4. Able and willing to give informed consent&#xD;
&#xD;
        Cohort 2 - Subjects with neovascular AMD&#xD;
&#xD;
          1. Age ≥ 50 years&#xD;
&#xD;
          2. History of neovascular age-related macular degeneration, in the study eye&#xD;
&#xD;
          3. Corrected distance or near VA of ≥ 20/200 Snellen equivalent, in the study eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cohort 1 - Normal subjects&#xD;
&#xD;
          1. History of ophthalmic disease resulting in decrease in visual acuity per the&#xD;
             Investigator, in the study eye&#xD;
&#xD;
          2. Use of any investigational drug in the past 30 days, or investigational,&#xD;
             interventional device in the past 60 days&#xD;
&#xD;
        Cohort 2 - Subjects with neovascular AMD&#xD;
&#xD;
          1. History of geographic atrophy or macular atrophy within the central 3 mm of the&#xD;
             macula, in the study eye&#xD;
&#xD;
          2. History of macular hole in the study eye&#xD;
&#xD;
          3. Use of any investigational drug in the past 30 days, or investigational,&#xD;
             interventional device in the past 60 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Gregory, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kubota Vision Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 17, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age-Related Macular Degeneration</keyword>
  <keyword>visual acuity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

